HomeGMAB • NASDAQ
add
Genmab A/S - ADR
Previous close
$20.47
Day range
$20.60 - $20.84
Year range
$20.34 - $32.88
Market cap
13.66B USD
Avg Volume
1.54M
In the news
Financials
Income Statement
Revenue
Net income
| (DKK) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 5.54B | 17.57% |
Operating expense | 3.15B | 6.78% |
Net income | 1.27B | -39.83% |
Net profit margin | 22.85 | -48.82% |
Earnings per share | 19.81 | 4,177.88% |
EBITDA | 2.20B | 26.09% |
Effective tax rate | 26.35% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 17.32B | -37.08% |
Total assets | 39.66B | 12.55% |
Total liabilities | 7.74B | 87.54% |
Total equity | 31.92B | — |
Shares outstanding | 63.51M | — |
Price to book | 0.04 | — |
Return on assets | 13.53% | — |
Return on capital | 16.33% | — |
Cash Flow
Net change in cash
| (DKK) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 1.27B | -39.83% |
Cash from operations | 2.03B | -0.20% |
Cash from investing | 224.00M | -77.78% |
Cash from financing | -276.00M | -1,480.00% |
Net change in cash | 2.01B | -40.84% |
Free cash flow | 1.42B | 9.09% |
About
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US. Wikipedia
Founded
1999
Website
Employees
2,635
